TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23809328
Drug: 1.6g of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6g of c9,t11CLA daily for two months
Study: 23809328
Drug: 3.2g of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2g of c9,t11CLA daily for two months
Study: 10827393
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment initiated within the first 1.5 hours (group A)
Study: 10827393
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early fibrinolytic therapy
Study: 17888558
Drug: 500‐mg GTPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mg GTPs
Study: 17888558
Drug: 1000‐mg GTPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000‐mg GTPs
Study: 15950853
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 1.0% ropivacaine with 1:200,000 epinephrine and analgesia with 0.2% ropivacaine at 8 mL/h, maintained for 7 days
Study: 15950853
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 0.5% bupivacaine and analgesia with intravenous patient‐controlled analgesia morphine, demand mode only
Study: 10569604
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg desmopressin
Study: 10569604
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg desmopressin
Study: 10569604
Drug: Anticholinergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic treatment
Study: 8935931
Drug: Diazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.03 mL/Kg of 5 mg/mL solution)
Study: 1714886
Drug: Amsacrine (AMSA)
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine (AMSA) at 100 mg/M2 daily for 5 days and etoposide at 200 mg/M2 daily for the first 3 days of therapy
Study: 1714886
Drug: Amsacrine (AMSA)
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine (AMSA) and etoposide plus azacitidine (AZ) at a dosage of 250 mg/M2 on days 4 and 5
Study: 25201459
Drug: tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.4 mg for 4 weeks
Study: 27811309
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole)
Study: 27811309
Drug: Guideline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline treatment (control group)
Study: 15752381
Drug: Ebastine +
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine + Ketoconazole (20 mg qd + 450 mg qd)
Study: 15752381
Drug: Loratadine +
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine + Ketoconazole (10 mg qd + 400 mg qd)
Study: 15752381
Drug: Ketoconazole +
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole + Placebo (450 mg qd or 400 mg qd)
Study: 15752381
Drug: Ebastine +
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine + Placebo (20 mg qd)
Study: 15752381
Drug: Loratadine +
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine + Placebo (10 mg qd)
Study: 12110818
Drug: HFA‐BDP Autohaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐BDP Autohaler at half the daily dose (100-200 microg)
Study: 7428401
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg, 1 dose
Study: 7428401
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg, 7 doses
Study: 7428401
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g, 1 dose
Study: 7428401
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g, 7 doses
Study: 17125424
Drug: Lactobacillus intravaginal
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus intravaginal capsule
Study: 17125424
Drug: Placebo intravaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravaginal capsule
Study: 14702508
Drug: Overall prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prescription rates (all groups)
Study: 2039190
Drug: Schedule 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 2 (30 mg/kg over 2 days; one dose of 10 mg/kg followed by two doses of 5 mg/kg at 6‐h intervals on the first day and two doses of 5 mg/kg at 12‐h intervals on the second day)
Study: 2039190
Drug: Schedule 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 1 (25 mg/kg over 3 days)
Study: 31793465
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 mL of tap water)
Study: 24606094
Drug: ω-3 FAEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 FAEE supplementation (4 g/d)
Study: 22500390
Drug: Zaizao Shengxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaizao Shengxue Tablet (ZST)
Study: 17559735
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa correction/maintenance dosing (4.5 microg/kg weekly for 4 weeks followed by 4.5 microg/kg every 3 weeks)
Study: 17559735
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa weekly dosing (2.25 microg/kg weekly)
Study: 17559735
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa correction/maintenance dosing
Study: 17559735
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa weekly dosing
Study: 10408592
Drug: Eprosartan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (200 or 300 mg b.i.d.)
Study: 10408592
Drug: Enalapril (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5‐20 mg u.i.d.)
Study: 7677298
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg administered alone
Study: 7677298
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg administered with didanosine placebo tablets (group 1)
Study: 7677298
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg administered with active didanosine tablets (group 2)
Study: 6754492
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g oral glucose tolerance test
Study: 31905410
Drug: Amniotic suspension
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic suspension allograft injection
Study: 17498420
Drug: 0.25 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 percent tetracycline aqueous solution mouthwash
Study: 18005429
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of folic acid
Study: 15160440
Drug: Rupatadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 20 mg (R20)
Study: 15160440
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg (R10)
Study: 1385586
Drug: Clodronate (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (3.2 g for the first month, thereafter 1.6 g)
Study: 1385586
Drug: Clodronate (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (3.2 g and 1.6 g)
Study: 1385586
Drug: Clodronate (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (3.2 g)
Study: 6719513
Drug: Computerized tomography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized tomography for localization of treatment volume
Study: 6719513
Drug: Conventional localization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional localization for treatment volume
Study: 27296126
Drug: Combined preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preventive measures (CPM) including antibiotic prophylaxis with IV amoxicillin/clavulanate (1.2 g)
Study: 15156418
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia (TIVA)
Study: 9840720
Drug: Corticosteroid co-medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid co-medication
Study: 9840720
Drug: Docetaxel without
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel without corticosteroid co-medication
Study: 9840720
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of docetaxel
Study: 8030804
Drug: nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nedocromil sodium, 2% ophthalmic solution, bid
Study: 30903806
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment of severe wasting
Study: 25447557
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine at 1 mg/kg
Study: 25447557
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl at 1.5 μg/kg
Study: 15384808
Drug: ACEI (oral)
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (oral)
Study: 15384808
Drug: ARB (oral)
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (oral)
Study: 15384808
Drug: Ca channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca channel blocker
Study: 10626618
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (child only)
Study: 10626618
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (mother only)
Study: 10626618
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (mother and child)
Study: 8748193
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) for three 3‐h periods daily
Study: 2202511
Drug: Ceftizoxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (1 gm single dose)
Study: 2202511
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2 gm)
Study: 19528280
Drug: PA-824 (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 (1,500 mg single dose)
Study: 19528280
Drug: PA-824 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 (600 mg multiple doses)
Study: 19528280
Drug: PA-824 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 (up to 7 days of daily dosing)
Study: 19528280
Drug: PA-824 (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 (daily dosing)
Study: 15068394
Drug: OGTT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT (oral glucose tolerance test; 75 g of glucose)
Study: 3557017
Drug: Sulfated G‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfated G‐17 infusion
Study: 3557017
Drug: Unsulfated G‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsulfated G‐17 infusion
Study: 30506924
Drug: Mirtazapine transdermal
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine transdermal ointment 2 mg/cat, applied once daily for 14 ± 3 days
Study: 30506924
Drug: Placebo, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied once daily for 14 ± 3 days
Study: 17329128
Drug: Dopamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine administration
Study: 10890672
Drug: Ibuprofen (cyclooxygenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (cyclooxygenase inhibitor)
Study: 7899118
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 2 mg/kg IV
Study: 3108981
Drug: Coughing during
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coughing during inhalation of nebulised distilled water
Study: 21468376
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime 1500 mg given as preoperative antimicrobial prophylaxis 30 minutes prior to surgery
Study: 16705719
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg alendronate for 2 months and 10 mg for 2 months thereafter
Study: 16705719
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg alendronate for 2 months and 10 mg for 4 months thereafter
Study: 14740310
Drug: Propofol-LCT with
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-LCT with pre-treatment of lidocaine
Study: 14740310
Drug: Propofol-MCT/LCT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-MCT/LCT with pre-treatment of lidocaine
Study: 11501728
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (ice massage or wax packs, thermal baths, and faradic hand baths)
Study: 11501728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no physical or exercise therapy)
Study: 9243041
Drug: Stopping antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping antibiotic therapy on day 3 (group A)
Study: 9243041
Drug: Continuing antibiotic
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing antibiotic therapy (group B)
Study: 3570863
Drug: Riboflavin supplement
Normalized name: Riboflavin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin supplement
Study: 3570863
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplement
Study: 28545578
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (MBI) involving eight workshops lasting 1.5 hours each, conducted weekly for 8 weeks.
Study: 26136584
Drug: WEP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEP group with high water intake (>1200 mL/d)
Study: 23670566
Drug: Counseling for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling for depression treatment
Study: 21172952
Drug: BI 44370
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 44370 TA 400 mg
Study: 21172952
Drug: BI 44370
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 44370 TA 200 mg
Study: 21172952
Drug: BI 44370
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 44370 TA 50 mg
Study: 16247610
Drug: Clotrimazole 100
Normalized name: clotrimazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 100 mg vaginal pessaries for 6 days, 2 gm secnidazole, and 150 mg fluconazole as single therapy.
Study: 16247610
Drug: Clotrimazole 100
Normalized name: clotrimazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 100 mg vaginal pessaries for 6 days, combination kit containing 150 mg fluconazole, 2 gm secnidazole, and 1 gm azithromycin.
Study: 12235022
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) 150 mg/kg body weight
Study: 10217372
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet/day)
Study: 8610776
Drug: Endocervical prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocervical prostaglandin E2 gel
Study: 540079
Drug: Tinidazole 40-50
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole 40-50 mg/kg for 3 days
Study: 540079
Drug: Tinidazole 100
Normalized name: tinidazole 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 100 mg coated tablets
Study: 540079
Drug: Tinidazole 40-50
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole 40-50 mg/kg
Study: 540079
Drug: Tinidazole for
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole for G. lamblia infections
Study: 22670574
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy program
Study: 17590368
Drug: Mud-bath treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath treatment (12 mud packs and 12 thermal baths over a period of two weeks)
Study: 2112337
Drug: ISDN spray,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN spray, 2.5 mg
Study: 2112337
Drug: sublingual NTG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual NTG, 0.8 mg
Study: 91774
Drug: Vaccinated group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated group (polyvalent pseudomonas vaccine)
Study: 31401603
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (HFOT) alone
Study: 31401603
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (HFOT) with non-invasive ventilation (NIV)
Study: 29669181
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily)
Study: 24598885
Drug: Vitamin B-12
Normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-12 supplementation (50 μg daily)
Study: 22856186
Drug: Gel-bead delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-bead delivery of Eimeria oocysts
Study: 22856186
Drug: Oral gavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gavage of Eimeria oocysts
Study: 22856186
Drug: Spray vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray vaccination with Eimeria oocysts mixture
Study: 20738316
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (5 pmol/kg/min)
Study: 18422391
Drug: High-dose valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valsartan 160-320 mg/day
Study: 18422391
Drug: Low-dose valsartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valsartan 80 mg/day (VALVACE trial)
Study: 10648316
Drug: 12-mL bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-mL bolus dose with a 25-min lockout interval
Study: 10648316
Drug: 4-mL bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mL bolus dose with an 8-min lockout interval
Study: 9017785
Drug: 5-lipoxygenase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-lipoxygenase inhibitors
Study: 9017785
Drug: cysLT receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cysLT receptor antagonists
Study: 9017785
Drug: 5-lipoxygenase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-lipoxygenase inhibitors and cysLT receptor antagonists
Study: 8382228
Drug: pyrophosphate containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrophosphate containing cleaning gel
Study: 3017551
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) - 80 mg/m2 iv daily X 3 every 6 weeks
Study: 3017551
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) - 175 mg/m2 iv daily X 5 every 4 weeks
Study: 3017551
Drug: Procarbazine (PCB)
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procarbazine (PCB) - 100 mg/m2 orally
Study: 22549390
Drug: Jiedu granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiedu granules plus cinobufacini injection (CM group)
Study: 20353469
Drug: 200 days
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 days valganciclovir prophylaxis (900 mg once daily)
Study: 20353469
Drug: 100 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 days valganciclovir prophylaxis (900 mg once daily)
Study: 18419349
Drug: High-potency live-attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine
Study: 15863796
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.m. of olanzapine
Study: 15863796
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg i.m. of haloperidol
Study: 11862501
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus MLT (20 mg/day orally during the dark period)
Study: 11862501
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus MLT (20 mg/day orally during the dark period)
Study: 1918275
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase (UK) 72,000 IU injected over 10 minutes and UK 528,000 IU by drip infusion over 12 or 24 hours (UK group, n = 76)
Study: 1918275
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without urokinase (control group, n = 90)
Study: 1918275
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase (UK) (UK group, n = 43)